Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.

2.50
Hdl Handle:
http://hdl.handle.net/10541/71925
Title:
Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.
Authors:
Sakhinia, Ebrahim; Glennie, Caroline; Hoyland, Judith A; Menasce, Lia P; Brady, Ged; Miller, Crispin J; Radford, John A ( 0000-0001-7898-2786 ) ; Byers, Richard J
Abstract:
Recent microarray gene expression profiling studies have identified gene signatures predictive of outcome, so-called "indicator" genes, for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). However, measurement of these genes in routine practice remains difficult. We applied real-time polymerase chain reaction (PCR) to polyA cDNAs prepared from 106 archived human frozen lymph nodes (63 of FL, 25 of DLBCL, 10 reactive lymph nodes, and cases with paired samples of FL [4] and subsequent DLBCL [4]). Reverse transcription and polyA reverse transcriptase (RT)-PCR was performed, and resultant cDNA was probed by real-time PCR for 36 candidate indicator genes, selected from microarray studies. Nine genes showed statistically significant different expression between FL and DLBCL, including cyclin B, COL3A1, NPM3, H731, PRKCB1, OVGL, ZFPC150, HLA-DQ-a, and XPB. Of these, cyclin B, NPM3, and COL3A1 were higher in DLBCL. Six genes showed statistically significant higher expression in the neoplastic nodes compared with reactive nodes, namely PRKCB1, BCL-6, EAR2, ZFX, cyclin B, YY1. High levels of YY.1 were associated with a shorter survival interval in both FL and DLBCL. The method is simple, sensitive, and robust, facilitating routine use and may be used as a platform for clinical measurement of prognostic gene signatures.
Affiliation:
Division of Regenerative Medicine, School of Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Oxford Road, Manchester, UK.
Citation:
Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. 2007, 109 (9):3922-8 Blood
Journal:
Blood
Issue Date:
1-May-2007
URI:
http://hdl.handle.net/10541/71925
DOI:
10.1182/blood-2006-09-046391
PubMed ID:
17255358
Type:
Article
Language:
en
ISSN:
0006-4971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSakhinia, Ebrahim-
dc.contributor.authorGlennie, Caroline-
dc.contributor.authorHoyland, Judith A-
dc.contributor.authorMenasce, Lia P-
dc.contributor.authorBrady, Ged-
dc.contributor.authorMiller, Crispin J-
dc.contributor.authorRadford, John A-
dc.contributor.authorByers, Richard J-
dc.date.accessioned2009-06-30T11:56:57Z-
dc.date.available2009-06-30T11:56:57Z-
dc.date.issued2007-05-01-
dc.identifier.citationClinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. 2007, 109 (9):3922-8 Blooden
dc.identifier.issn0006-4971-
dc.identifier.pmid17255358-
dc.identifier.doi10.1182/blood-2006-09-046391-
dc.identifier.urihttp://hdl.handle.net/10541/71925-
dc.description.abstractRecent microarray gene expression profiling studies have identified gene signatures predictive of outcome, so-called "indicator" genes, for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). However, measurement of these genes in routine practice remains difficult. We applied real-time polymerase chain reaction (PCR) to polyA cDNAs prepared from 106 archived human frozen lymph nodes (63 of FL, 25 of DLBCL, 10 reactive lymph nodes, and cases with paired samples of FL [4] and subsequent DLBCL [4]). Reverse transcription and polyA reverse transcriptase (RT)-PCR was performed, and resultant cDNA was probed by real-time PCR for 36 candidate indicator genes, selected from microarray studies. Nine genes showed statistically significant different expression between FL and DLBCL, including cyclin B, COL3A1, NPM3, H731, PRKCB1, OVGL, ZFPC150, HLA-DQ-a, and XPB. Of these, cyclin B, NPM3, and COL3A1 were higher in DLBCL. Six genes showed statistically significant higher expression in the neoplastic nodes compared with reactive nodes, namely PRKCB1, BCL-6, EAR2, ZFX, cyclin B, YY1. High levels of YY.1 were associated with a shorter survival interval in both FL and DLBCL. The method is simple, sensitive, and robust, facilitating routine use and may be used as a platform for clinical measurement of prognostic gene signatures.en
dc.language.isoenen
dc.subjectCancer Proteinsen
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshGene Expression Profiling-
dc.subject.meshGene Expression Regulation, Leukemic-
dc.subject.meshHumans-
dc.subject.meshLymphoma, B-Cell-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshLymphoma, Large B-Cell, Diffuse-
dc.subject.meshMale-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshOligonucleotide Array Sequence Analysis-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshPrognosis-
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction-
dc.subject.meshSurvival Rate-
dc.titleClinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.en
dc.typeArticleen
dc.contributor.departmentDivision of Regenerative Medicine, School of Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Oxford Road, Manchester, UK.en
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.